TP53 and small cell lung carcinoma: As depicted in Fig. 1A, among the first 600 patients diagnosed with de novo SCLC who underwent sequencing by MSK-IMPACT, 20 (3%) exhibited RB1 and TP53 dual proficiency, defined by an integrated genomic and IHC approach (Supplementary Table S1).